Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 3/20 | 0.66 |
| ▸ | MMP8 | P22894 | 3/20 | 0.66 |
| ▸ | MMP14 | P50281 | 1/20 | 0.66 |
| ▸ | PYGL | P06737 | 10/20 | 0.53 |
| ▸ | MMP3 | P08254 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12225561 | 1.00 | MMP9 (0.66) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL6319141 | 1.00 | MMP9 (0.66) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL8190605 | 0.87 | MMP9 (0.51) | MMP9MMP8MMP14PYGLHPGD | |
| SCHEMBL8218362 | 0.87 | MMP9 (0.51) | MMP9MMP8MMP14PYGLHPGD | |
| SCHEMBL3266638 | 0.87 | MMP9 (0.51) | MMP9MMP8MMP14PYGLHPGD | |
| SCHEMBL16254314 | 0.85 | HPGD (0.65) | MMP9MMP8MMP14HPGD | |
| SCHEMBL24414099 | 0.85 | MMP9 (0.73) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL15387081 | 0.85 | MMP9 (0.64) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL25410860 | 0.85 | MMP9 (0.73) | MMP9MMP8MMP14PYGLMMP3 | |
| SCHEMBL13354879 | 0.84 | MMP9 (0.49) | MMP9MMP8MMP14PYGLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018102006-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE ACTIVITY AND USE THEREOF | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2018-06-07 | — | — | WO | claimed |
| WO-2018102006-A1 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE ACTIVITY AND USE THEREOF | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2018-06-07 | — | — | WO | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
| CN-1211991-A | Compounds with growth hormone releasing properties | NOVO NORDISK AS (DK) | 1999-03-24 | — | — | CN | disclosed |
| EP-0869974-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023508-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | MMP9 2831/4885MMP8 4280/4885MMP14 3609/4885 |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, MAPKAP1, PIK3R5 | MMP9 3710/4885MMP8 4197/4885MMP14 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.